Genetic Technologies pulls back after Announcing $5M Registered Direct Offering
Editor’s note- Due to a technical issue, this is a delayed post
(24/7 MARKET NEWS) – Genetic Technologies (NASDAQ: GENE) opened this morning’s premarket at $3.86, following yesterday’s post market news of an approaching launch Of world’s first comprehensive breast and ovarian cancer risk test. It was trading near the $3 level, when it pulled back on the news of a $5 million registered direct offering
Genetic Technologies is trading at $1.51, up $0.500 (+49.50%), on 18.76million premarket shares.
Its 52-week range is $0.83 to $2.13. It’s bouncing off its 52-week low that it hit January 30. Today’s premarket trading levels were last seen in 2021.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
